{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:26:59Z","timestamp":1790029619523,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study evaluates upadacitinib (UPA) effectiveness and drug retention rate (DRR) in patients with rheumatoid arthritis (RA). Multicentre prospective observational study. Consecutive patients with RA receiving UPA were evaluated at 0, 3, 6, 12, 18, and 24\u00a0months of treatment. Key outcomes included UPA DRR and changes in clinical and serological measures over time. The study included 215 patients (72.6% female sex, mean age 60.1\u2009\u00b1\u200911.7\u00a0years). The DRR of UPA was 91.6% (95% CI 88.0\u201395.4%) at 6\u00a0months, 84.6% (95% CI 79.8\u201389.7%) at 12\u00a0months, 80.3% (95% CI 75.0\u201386.0%) at 18\u00a0months and 80% (95% CI 75.0\u201386.0%) at 24\u00a0months. UPA DRR was similar between monotherapy and methotrexate combination (p\u2009=\u20090.47), and across different treatment lines (p\u2009=\u20090.58). A statistically significant improvement from baseline was observed over 24\u00a0months considering erythrocyte sedimentation rate, C-reactive protein (CRP), Health Assessment Questionnaire (HAQ), Disease Activity Score (DAS)28-CRP, Physician\u2019s (Ph) and Patient\u2019s (Pt) Global Assessment (GA), Visual Analogue Scale (VAS) Pain, Simplified and Clinical Disease Activity Index (SDAI and\u00a0CDAI) (p\u2009&lt;\u20090.00 for all of them). Patients discontinuing UPA were more likely to be male (p\u2009=\u20090.02), with a longer disease duration (p\u2009=\u20090.03), higher baseline values of VAS Pain (p\u2009&lt;\u20090.00), PtGA (p\u2009&lt;\u20090.00), PhGA (p\u2009&lt;\u20090.00), CDAI (p\u2009&lt;\u20090.00), SDAI (p\u2009&lt;\u20090.00) and corticosteroid dosage (p\u2009=\u20090.04). This study confirms UPA effectiveness in managing RA in the real-world practice, demonstrating sustained drug retention and improvements in clinical and laboratory measures over time. Also, UPA could be a valuable option for patients with multi-refractory RA and when monotherapy is preferred.<\/jats:p>","DOI":"10.1007\/s10238-025-01578-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:11:52Z","timestamp":1738768312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study"],"prefix":"10.1007","volume":"25","author":[{"given":"Caterina","family":"Baldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Li Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Delle Sedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"D\u2019Ignazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Cato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Picchianti-Diamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"1","key":"1578_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s41927-022-00308-5","volume":"6","author":"A Ben Tekaya","year":"2022","unstructured":"Ben Tekaya A, Hannech E, Saidane O, et al. Association between Rheumatic Disease Comorbidity Index and factors of poor prognosis in a cohort of 280 patients with rheumatoid arthritis. BMC Rheumatol. 2022;6(1):78. https:\/\/doi.org\/10.1186\/s41927-022-00308-5.","journal-title":"BMC Rheumatol"},{"issue":"2","key":"1578_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","volume":"32","author":"D van der Woude","year":"2018","unstructured":"van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174\u201387. https:\/\/doi.org\/10.1016\/j.berh.2018.10.005.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"1578_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028501","volume":"101","author":"KH Yu","year":"2022","unstructured":"Yu KH, Chen HH, Cheng TT, et al. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine. 2022;101(1): e28501. https:\/\/doi.org\/10.1097\/MD.0000000000028501.","journal-title":"Medicine"},{"issue":"1","key":"1578_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):95\u2013106. https:\/\/doi.org\/10.1136\/ard-2022-223365.","journal-title":"Ann Rheum Dis"},{"key":"1578_CR5","doi-asserted-by":"publisher","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68(1):1\u201325. https:\/\/doi.org\/10.1002\/acr.22783.","DOI":"10.1002\/acr.22783"},{"issue":"9410","key":"1578_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (trial of etanercept and methotrexate with radiographic patient outcomes) study investigators. therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(04)15640-7.","journal-title":"Lancet"},{"issue":"6","key":"1578_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/acr.20452","volume":"63","author":"DE Furst","year":"2011","unstructured":"Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the consortium of rheumatology researchers of north America registry. Arthritis Care Res. 2011;63(6):856\u201364. https:\/\/doi.org\/10.1002\/acr.20452.","journal-title":"Arthritis Care Res"},{"issue":"9688","key":"1578_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(09)60944-2.","journal-title":"Lancet"},{"issue":"12","key":"1578_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707\u201318. https:\/\/doi.org\/10.1038\/nrrheum.2017.187.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1578_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204577.","journal-title":"Ann Rheum Dis"},{"issue":"9865","key":"1578_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X.","journal-title":"Lancet"},{"issue":"11","key":"1578_CR12","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516\u201323. https:\/\/doi.org\/10.1136\/ard.2008.092932.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1578_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370. https:\/\/doi.org\/10.1056\/NEJMra1202117.","journal-title":"N Engl J Med"},{"issue":"12","key":"1578_CR14","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/art.39801","volume":"68","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867\u201377. https:\/\/doi.org\/10.1002\/art.39801.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1578_CR15","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857\u201366. https:\/\/doi.org\/10.1002\/art.39808.","journal-title":"Arthritis Rheumatol"},{"issue":"10139","key":"1578_CR16","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"Lancet"},{"issue":"1","key":"1578_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1): e13688. https:\/\/doi.org\/10.1111\/cts.13688.","journal-title":"Clin Transl Sci"},{"issue":"10139","key":"1578_CR18","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4.","journal-title":"Lancet"},{"issue":"11","key":"1578_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215764.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1578_CR20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind. Randomized Controlled Trial Arthritis Rheumatol. 2019;71(11):1788\u2013800. https:\/\/doi.org\/10.1002\/art.41032.","journal-title":"Randomized Controlled Trial Arthritis Rheumatol"},{"key":"1578_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/annrheumdis-2019-eular.3082","volume":"78","author":"GR Burmester","year":"2019","unstructured":"Burmester GR, Bosch FVD, Bessette L, et al. FRI0132 long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: Results at 60 weeks from the SELECT-NEXT study. Ann Rheum Dis. 2019;78:735\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"10188","key":"1578_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2.","journal-title":"Lancet"},{"issue":"10","key":"1578_CR23","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind. Active Comparator-Controlled Trial Arthritis Rheumatol. 2020;72(10):1607\u201320. https:\/\/doi.org\/10.1002\/art.41384.","journal-title":"Active Comparator-Controlled Trial Arthritis Rheumatol"},{"key":"1578_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2020-eular.2059","volume":"79","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan A, et al. SAT0151 Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, randomized controlled Phase 3 trial. Ann Rheum Dis. 2020;79:1011. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.2059.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1578_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","volume":"23","author":"H Kameda","year":"2021","unstructured":"Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23(1):9. https:\/\/doi.org\/10.1186\/s13075-020-02387-6.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1578_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/jcm13020401","volume":"13","author":"C Baldi","year":"2024","unstructured":"Baldi C, Parisi S, Falsetti P, et al. Efficacy and safety of upadacitinib in rheumatoid arthritis: real-life experience from a prospective longitudinal multicentric study. J Clin Med. 2024;13(2):401. https:\/\/doi.org\/10.3390\/jcm13020401.","journal-title":"J Clin Med"},{"key":"1578_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes279","author":"J Kay","year":"2010","unstructured":"Kay J, Upchurch KSACR, EULAR,. Rheumatoid arthritis classification criteria. Rheumatology. 2010. https:\/\/doi.org\/10.1093\/rheumatology\/kes279.","journal-title":"Rheumatology"},{"key":"1578_CR28","doi-asserted-by":"publisher","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","DOI":"10.1002\/art.1780380107"},{"issue":"4","key":"1578_CR29","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806. https:\/\/doi.org\/10.1186\/ar1740.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1578_CR30","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.3390\/jcm13123494","volume":"13","author":"D Donzella","year":"2024","unstructured":"Donzella D, Bellis E, Crepaldi G, et al. The retention rate and safety of JAK inhibitors in rheumatoid arthritis: real word data from a monocentric cohort. J Clin Med. 2024;13(12):3494. https:\/\/doi.org\/10.3390\/jcm13123494.","journal-title":"J Clin Med"},{"issue":"1","key":"1578_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, et al. Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2020;22(1):142. https:\/\/doi.org\/10.1186\/s13075-020-02232-w.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1578_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","volume":"54","author":"H Forsblad-d'Elia","year":"2015","unstructured":"Forsblad-d\u2019Elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology. 2015;54(7):1186\u201393. https:\/\/doi.org\/10.1093\/rheumatology\/keu455.","journal-title":"Rheumatology"},{"issue":"12","key":"1578_CR33","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","volume":"78","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Maa JF, Chen S, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214918.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1578_CR34","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology. 2021;60(9):4048\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keaa858.","journal-title":"Rheumatology"},{"key":"1578_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2024.100178","volume":"6","author":"S Parisi","year":"2024","unstructured":"Parisi S, Andrea B, Chiara DM, et al. Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients. Curr Res Pharmacol Drug Discov. 2024;6: 100178. https:\/\/doi.org\/10.1016\/j.crphar.2024.100178.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"1578_CR36","doi-asserted-by":"publisher","first-page":"1176613","DOI":"10.3389\/fmed.2023.1176613","volume":"10","author":"C Baldi","year":"2023","unstructured":"Baldi C, Berlengiero V, Falsetti P, et al. Baricitinib retention rate: \u2018real-life\u2019 data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front Med (Lausanne). 2023;10:1176613. https:\/\/doi.org\/10.3389\/fmed.2023.1176613.","journal-title":"Front Med (Lausanne)"},{"key":"1578_CR37","doi-asserted-by":"publisher","unstructured":"Fornaro M, Caporali R, Biggioggero M, et al; from the GISEA registry. Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry. Clin Exp Rheumatol. 2024;42(5):1043\u20131050. https:\/\/doi.org\/10.55563\/clinexprheumatol\/b40rv4.","DOI":"10.55563\/clinexprheumatol\/b40rv4"},{"issue":"8","key":"1578_CR38","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/medicina59081480","volume":"59","author":"M Paroli","year":"2023","unstructured":"Paroli M, Becciolini A, Bravi E, et al. Long-term retention rate of tofacitinib in rheumatoid arthritis: an italian multicenter retrospective cohort study. Medicina (Kaunas). 2023;59(8):1480. https:\/\/doi.org\/10.3390\/medicina59081480.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"1578_CR39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s40744-024-00712-y","volume":"11","author":"A Picchianti Diamanti","year":"2024","unstructured":"Picchianti Diamanti A, Cattaruzza MS, Salemi S, et al. Clinical and ultrasonographic remission in bio-na\u00efve and bio-failure patients with rheumatoid arthritis at 24 weeks of upadacitinib treatment: the UPARAREMUS real-life study. Rheumatol Ther. 2024;11(5):1347\u201361. https:\/\/doi.org\/10.1007\/s40744-024-00712-y.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1578_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","volume":"14","author":"C Martinez-Molina","year":"2024","unstructured":"Martinez-Molina C, Gich I, Diaz-Torn\u00e9 C, et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172. https:\/\/doi.org\/10.1038\/s41598-023-50379-8.","journal-title":"Sci Rep"},{"issue":"1","key":"1578_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10238-024-01325-z","volume":"24","author":"S Gentileschi","year":"2024","unstructured":"Gentileschi S, Gaggiano C, Damiani A, et al. Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort. Clin Exp Med. 2024;24(1):62. https:\/\/doi.org\/10.1007\/s10238-024-01325-z.","journal-title":"Clin Exp Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01578-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:54Z","timestamp":1764917514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01578-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01578-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (no individual person\u2019s data are reported).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Siena (Reference No. Rhelabus 22271).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"50"}}